Humacyte Inc (NAS:HUMA)

$ 8.79 0.39 (4.64%) Market Cap: 1.05 Bil Enterprise Value: 903.37 Mil PE Ratio: 0 PB Ratio: 39.95 GF Score: 20/100

Q1 2024 Humacyte Inc Earnings Call Transcript
May 10, 2024

$4.7 (+3.98%)

Earnings
Q4 2023 Humacyte Inc Earnings Call Transcript
Mar 22, 2024

$3.31 (-8.06%)

Earnings
Q3 2023 Humacyte Inc Earnings Call Transcript
Nov 09, 2023

$2.21 (+0.91%)

Earnings
Humacyte Inc To Host KOL And Patient Perspectives Event Transcript
Sep 20, 2023
Humacyte Inc Top Line Data Announcement Transcript
Sep 12, 2023
Q2 2023 Humacyte Inc Earnings Call Transcript
Aug 14, 2023

$4.04 (+23.55%)

Earnings
Q1 2023 Humacyte Inc Earnings Call Transcript
May 12, 2023

$3.97 (-6.48%)

Earnings
Humacyte Inc at H.C. Wainwright BioConnect Investor Conference Transcript
May 02, 2023
Q4 2022 Humacyte Inc Earnings Call Transcript
Mar 24, 2023

$2.91 (-5.83%)

Earnings
Humacyte Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
Mar 14, 2023
Humacyte Inc at Cowen Health Care Conference Transcript
Mar 06, 2023
Humacyte Inc At Emerging Growth Conference (Virtual) Transcript
Feb 08, 2023
Humacyte Inc KOL Webinar: Ukrainian Surgeons Discuss Use of HAV in Wartime Transcript
Dec 15, 2022
Q3 2022 Humacyte Inc Earnings Call Transcript
Nov 10, 2022

$3.26 (+3.82%)

Earnings
Q4 2021 Humacyte Inc Earnings Call Transcript
Mar 29, 2022

$6.73 (+5.65%)

Earnings

Humacyte Inc Top Line Data Announcement Transcript

Sep 12, 2023 / 12:00PM GMT

Release Date Price: $3.88 (+4.86%)

Transcript

Operator

Good afternoon, and welcome to the Humacyte data call. (Operator Instructions) At this time, I would now like to turn the call over to your host, Laura Niklason, Chief Executive Officer of Humacyte. Please go ahead, Laura.

Laura E. Niklason

Humacyte, Inc. - Founder, President, CEO & Director

Thank you, Sarah, and welcome, everyone, to our top line results and KOL webinar call regarding our CLN-PRO-V005 trial of the HAV in vascular trauma. This is Humacyte's typical disclaimers regarding forward-looking statements. Just as a reminder to those on the call, Humacyte really leads the field of regenerative medicine in the bioengineering of tissues and organs. Our human acellular vessel or HAV is available off the shelf and is universally implantable with no immunosuppression.

In addition, we've observed that the HAV repopulates with cells from the patient over time after implantation, becoming a living tissue. We believe this is category-defining innovation that creates new tissues for patients with a variety of medical conditions. If we look now at

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.